Postgraduate Program, Northeast Biotechnology Network (Rede Nordeste de Biotecnologia - RENORBIO), Federal University of Piaui, Teresina, Piauí, 64049-550, Brazil.
Postgraduate Program in Health Sciences, Federal University of Piaui, Teresina, 64049-550, Brazil.
Med Oncol. 2017 Aug 11;34(9):161. doi: 10.1007/s12032-017-1022-2.
Biomarkers for the prognosis of breast cancer have been routinely used in clinical practice, including the expression of hormone receptors, Ki-67 and HER-2. More recently, Bcl-2 has been recognized as an important prognostic factor in breast cancer, although controversies persist with respect to the significance of its expression. The aim of the present study was to evaluate Bcl-2 antigen expression in luminal A and triple-negative breast cancer. Sixty women with invasive ductal carcinoma were included in the study and divided into two groups: Group A (luminal A) and Group B (triple-negative), with 30 cases in each group. Immunohistochemistry was performed on tissue sections to evaluate Bcl-2 antigen expression. Fisher's exact test was used to compare the proportions of cases with cells expressing Bcl-2 between the two subtype cancer groups, with statistical significance being established at p < 0.05. The number of cases with cells expressing Bcl-2 in Groups A and B was 26 (86.7%) and 12 (40.0%), respectively (p < 0.0003). In the present study, the expression of the anti-apoptotic protein Bcl-2 was greater in luminal A breast cancer tissue samples compared to triple-negative breast cancer.
用于乳腺癌预后的生物标志物已在临床实践中常规使用，包括激素受体、Ki-67 和 HER-2 的表达。最近，Bcl-2 已被认为是乳腺癌的一个重要预后因素，尽管其表达的意义仍存在争议。本研究旨在评估 Bcl-2 抗原在腔 A 型和三阴性乳腺癌中的表达。将 60 名浸润性导管癌女性纳入研究，并分为两组：A 组（腔 A 型）和 B 组（三阴性），每组 30 例。对组织切片进行免疫组织化学染色，以评估 Bcl-2 抗原的表达。Fisher 确切概率法用于比较两组亚型癌症中表达 Bcl-2 的细胞比例，p<0.05 具有统计学意义。A 组和 B 组中表达 Bcl-2 的细胞数分别为 26 例（86.7%）和 12 例（40.0%）（p<0.0003）。在本研究中，与三阴性乳腺癌相比，腔 A 型乳腺癌组织样本中抗凋亡蛋白 Bcl-2 的表达更高。
